SALT LAKE CITY--(BUSINESS WIRE)--Reprogenetics, Recombine, and Genesis Genetics are pleased to announce their joint presence as part of the CooperSurgical family at the American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo, in Salt Lake City, Utah from October 15 to 19. The companies are hosting a joint exhibit at booth 1607 in the Expo Hall, showcasing their technology and test offerings for pre-implantation genetic diagnosis and screening (PGD, PGS), expanded carrier screening (ECS), and non-invasive prenatal screening (NIPS).
In addition, the companies are holding their inaugural speaker series at their satellite booth, 805. The series will include six brief presentations by experts and practicing physicians in the field of reproductive genetics, with opportunity for attendees to engage in active discussion. Speakers will address some of the latest topics, such as access to fertility care and the impact of mosaicism. A schedule of talks and titles is available to view at the booth.
As leaders in the field of reproductive genetic testing, scientists from Reprogenetics, Recombine, and Genesis Genetics – along with their clinical partners - are presenting thirty-six accepted abstracts at the Scientific Congress, sixteen as oral and twenty as poster presentations. Included in their presentations are two award-winning abstracts. The paper “Transfer Fresh or Vitrify After Blastocyst Biopsy? Results of an RCT” was selected as the Society for Assisted Reproductive Technology (SART) Prize Paper. First author Alison Coates of Oregon Reproductive Medicine will give the presentation on Tuesday, October 18 at 11:15 AM MDT. Selected as a Scientific Prize Paper, “Low Level Mosaicism: Incidence and Implications on Clinical Pregnancies”, will be presented by first author Dawn Kelk of Yale Fertility Center on Tuesday, October 18 at 12:30 PM MDT.
“We are excited to hear the latest advances from the innovative scientists across all three companies,” said Robert Auerbach, MD, Executive Vice President, Chief Strategy and Medical Officer at CooperSurgical. “Reprogenetics, Recombine, and Genesis Genetics have driven the field of reproductive genetic testing, and we look forward to using the power of this wealth of expertise to bring even more advances to our clinical partners.”
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women’s health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has approximately 10,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.